RxDoctor Payments Data

Allan Crimm, MD

Internal Medicine · Philadelphia, PANPI 1720089170

Payments from drug & device makers

$6,240in general payments, 2019–2025

Across 337 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$990
  • Pfizer$920
  • AbbVie$746
  • Astellas Pharma US Inc$467
  • AstraZeneca$370
  • Amgen$246
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,216100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,240 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$180,805
Medicare patients
678
Services billed
4,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$202,338
OzempicSemaglutide74$80,875
FarxigaDapagliflozin Propanediol73$78,197
TrulicityDulaglutide40$44,275
BiktarvyBictegrav/Emtricit/Tenofov Ala11$42,917
MyrbetriqMirabegron55$38,230
MounjaroTirzepatide29$37,373
JardianceEmpagliflozin35$35,871
Breo ElliptaFluticasone/Vilanterol73$31,124
TivicayDolutegravir Sodium13$30,318
DescovyEmtricitabine/Tenofov Alafenam13$29,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,675
LinzessLinaclotide45$24,143
XareltoRivaroxaban32$23,252
VascepaIcosapent Ethyl29$20,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$920$202,338220 claims
Lilly USA, LLCTrulicity, Mounjaro$198$81,64869 claims
Novo NordiskOzempic$990$80,87574 claims
AstraZenecaFarxiga$370$78,19773 claims
GileadBiktarvy, Descovy$219$72,49624 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy$119$71,523149 claims
Astellas Pharma US IncMyrbetriq$467$38,23055 claims
Boehringer IngelheimJardiance$206$35,87135 claims
AbbVieLinzess$746$24,14345 claims
Johnson & JohnsonXarelto$38$23,25232 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$160$7,03613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →